A phase I-II dose finding and early efficacy study of combination therapy with erlotinib (Tarceva), gemcitabine, bevacizumab (Avastin), and capecitabine in advanced pancreatic cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab; Capecitabine; Erlotinib; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TARGET
- 14 Oct 2016 Biomarkers information updated
- 12 Jan 2010 Planned end date changed from 1 Dec 2008 to 1 Dec 2009 as reported by ClinicalTrials.gov.
- 12 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.